Breaking News Instant updates and real-time market news.

NBIX

Neurocrine

$45.00

-1.58 (-3.39%)

, TEVA

Teva

$44.56

-0.48 (-1.07%)

06:27
10/12/16
10/12
06:27
10/12/16
06:27

Neurocrine recent selloff a buying opportunity, says Leerink

Leerink analyst Paul Matteis views the 18% pullback in shares of Neurocrine Biosciences (NBIX) over the past few weeks as a buying opportunity. The analyst finds the catalyst for the selloff "difficult to pinpoint," but notes he's been receiving questions from investors on the size of the market opportunity for vesicular monoamine transporters in Tardive Dyskinesia. A doctor survey suggests a target market of 300,000 TD patients for Neurocrine's and Teva's VMAT2 inhibitors, which is enough to offer a "significant revenue opportunity" for both drugs, Matteis tells investors in a research note. Further, the analyst believes the upcoming Phase II data in Tourette's Syndrome, which he sees as having a high probability of success, offers a "nice catalyst for investors" into Q1 of next year. Matteis reiterates an Outperform rating on Neurocrine with a $70 price target.

NBIX

Neurocrine

$45.00

-1.58 (-3.39%)

TEVA

Teva

$44.56

-0.48 (-1.07%)

  • 06

    Nov

  • 15

    Nov

  • 14

    Dec

NBIX Neurocrine
$45.00

-1.58 (-3.39%)

06/29/16
HCWC
06/29/16
INITIATION
Target $80
HCWC
Buy
Neurocrine initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started Neurocrine Biosciences with a Buy rating and $80 price target.
09/23/16
LEER
09/23/16
NO CHANGE
LEER
Outperform
Positive data paves way for Teva SD-809 indication, says Leerink
Leerink analyst Jason Gerberry says the AIM-TD study readout clinically de-risks Teva's (TEVA) SD-809 opportunity for tardive dyskinesia, with the investor focus shifting to market size and competitive differentiation versus Neurocrine's (NBIX) valbenazine. The analyst believes Teva's SD-809 is well positioned to compete against valbenazine with an equally efficacious and well tolerated drug. Further, he expects Teva to exit 2017 with a broader label. Gerberry reiterates an Outperform rating on Teva's shares.
10/04/16
LEER
10/04/16
INITIATION
Target $70
LEER
Outperform
Neurocrine reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Neurocrine with an Outperform rating and $70 price target.
10/06/16
LEHM
10/06/16
DOWNGRADE
Target $50
LEHM
Equal Weight
Alnylam downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Geoff Meacham downgraded Alnylam Pharmaceuticals (ALNY) to Equal Weight saying he views other SMid cap biotech names as more attractive following the company's recent pipeline setbacks. The analyst removed Revusiran sales from his Alnylam model after the program was discontinued yesterday and he cut his price target for the shares to $50 from $85. Meacham lists Neurocrine (NBIX), Prothena (PTRA) and Incyte (INCY) as names he finds more attractive over the next 12 months. Alnylam is trading down 44% in pre-market trading to $39.25.
TEVA Teva
$44.56

-0.48 (-1.07%)

10/05/16
WELS
10/05/16
NO CHANGE
WELS
Outperform
Teva estimates lowered on generic trends at Wells Fargo
Wells Fargo analyst David Maris lowered his estimates for Teva (TEVA) for this year and next, citing expectations for lower generic sales this year and lower margins in the generic business. Maris lowered his price target range for Teva shares to $60-$61 from $70-73 based on his lower estimates as well as the uncertainty of the environment, but keeps an Outperform rating on shares citing valuation and his belief 2017 should be a better year with several pipeline events for Teva.
10/06/16
WELS
10/06/16
NO CHANGE
WELS
Wells calls Teva partnership with Celltrion 'good news'
Wells Fargo analyst David Maris views Teva Pharmaceutical's partnership to commercialize two of Celltrion's monoclonal antibody biosimilar candidates as "good news." Teva is now a "little more firmly in the biosimilar game," Maris tells investors in a research note. He likes that the initial cash outflow is small and the partner. Maris has an Outperform rating on Teva.
10/07/16
LEER
10/07/16
NO CHANGE
Target $57
LEER
Outperform
Teva price target lowered to $57 from $61 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva to $57 from $61 and trimmed his estimates to reflect near-term headwinds and a more conservative Copaxone outlook. The analyst continues to view a generic Copaxone launch in late the second half of 2017 as a risk. Nonetheless, Gerberry reiterates an Outperform rating on the stock as he views shares as attractively valued despite near-term EPS concerns and believes investor attention will eventually pivot to Teva's attractive late stage pipeline.
10/11/16
LEHM
10/11/16
UPGRADE
Target $19
LEHM
Overweight
Momenta upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Douglas Tsao upgraded Momenta Pharmaceuticals to Overweight after attending the consolidated Copaxone 40mg trial. The analyst sees low risk of Momenta being blocked from the 40mg opportunity past 2018 and views the stock's risk/reward as "compelling" at current levels. Tsao believes there is a "good likelihood" that Sandoz, Momenta's partner, launches Copaxone 40mg at-risk as soon as February 2017 upon FDA approval when the 30-month stay expires. The analyst raised his price target for Momenta shares to $19 from $13.

TODAY'S FREE FLY STORIES

INFY

Infosys

$14.84

0.065 (0.44%)

11:34
06/23/17
06/23
11:34
06/23/17
11:34
Hot Stocks
Infosys reports auditors found no evidence of wrongdoing »

Infosys announced earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INFY

Infosys

$14.84

0.065 (0.44%)

11:31
06/23/17
06/23
11:31
06/23/17
11:31
Hot Stocks
NY AG Schneiderman announces $1M settlement with Infosys »

New York Attorney General…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDC

Western Digital

$90.25

-0.78 (-0.86%)

11:25
06/23/17
06/23
11:25
06/23/17
11:25
Options
Western Digital call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VLKAY

Volkswagen

$30.88

0.6 (1.98%)

11:22
06/23/17
06/23
11:22
06/23/17
11:22
Periodicals
VW reducing workforce at core unit more quickly than planned, Reuters says »

Volkswagen is cutting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

11:18
06/23/17
06/23
11:18
06/23/17
11:18
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

$NSD

NASDAQ Market Internals

11:17
06/23/17
06/23
11:17
06/23/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
06/23/17
06/23
11:16
06/23/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALE

Vale

$8.22

0.12 (1.48%)

11:10
06/23/17
06/23
11:10
06/23/17
11:10
Options
10K VALE Jan 10 calls trade at 40c on ISE »

10K VALE Jan 10 calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NURO

NeuroMetrix

$2.89

0.056 (1.98%)

11:08
06/23/17
06/23
11:08
06/23/17
11:08
Hot Stocks
NeuroMetrix provides update on Quell wearable pain relief clinical program »

NeuroMetrix provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAT

Caterpillar

$103.76

-0.08 (-0.08%)

11:08
06/23/17
06/23
11:08
06/23/17
11:08
Hot Stocks
As bar gets raised Deutsche Bank gets less bullish on Caterpillar »

Deutsche Bank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.87

0.44 (3.85%)

11:04
06/23/17
06/23
11:04
06/23/17
11:04
Earnings
Horizon Pharma now sees FY17 net sales $985M-$1.02B, consensus $990.53M »

In May, Horizon lowered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.87

0.44 (3.85%)

11:02
06/23/17
06/23
11:02
06/23/17
11:02
Hot Stocks
Horizon Pharma completes sale of European marketing rights for Procysbi »

Horizon Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UUP

PowerShares DB US Dollar Index Up

$25.14

-0.09 (-0.36%)

11:00
06/23/17
06/23
11:00
06/23/17
11:00
Options
Large spread in UPS as shares deliver gains »

Large spread in UPS as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
06/23/17
06/23
11:00
06/23/17
11:00
General news
Breaking General news story  »

St. Louis Federal Reserve…

10:55
06/23/17
06/23
10:55
06/23/17
10:55
General news
Euro$ interest rate futures are marginally lower »

Euro$ interest rate…

NVO

Novo Nordisk

$44.13

0.46 (1.05%)

10:52
06/23/17
06/23
10:52
06/23/17
10:52
Hot Stocks
Novo Nordisk reports up to 13.8% weight loss in people receiving semaglutide »

Novo Nordisk announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UPS

UPS

$110.54

1.469 (1.35%)

10:45
06/23/17
06/23
10:45
06/23/17
10:45
Options
UPS call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

WMGI

Wright Medical

$26.99

0.11 (0.41%)

10:45
06/23/17
06/23
10:45
06/23/17
10:45
Conference/Events
Wright Medical has a conference call hosted by JPMorgan »

JPMorgan Analyst Hanover…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Jun

  • 28

    Jun

  • 03

    Jul

WDC

Western Digital

$90.25

-0.78 (-0.86%)

10:40
06/23/17
06/23
10:40
06/23/17
10:40
Technical Analysis
Technical View: Western Digital trades higher as Toshiba indicates open to talks »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNCR

Synchronoss

$12.18

1.53 (14.37%)

10:31
06/23/17
06/23
10:31
06/23/17
10:31
Hot Stocks
Synchronoss confirms receipt of Siris Capital indication of interest »

Synchronoss Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$50.81

0.175 (0.35%)

10:31
06/23/17
06/23
10:31
06/23/17
10:31
Periodicals
Target starts removing all Hampton Creek products from stores, Bloomberg reports »

Target is voluntarily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:30
06/23/17
06/23
10:30
06/23/17
10:30
General news
The 2.9% May U.S. new home sales rise »

The 2.9% May U.S. new…

YY

YY

$58.32

-0.66 (-1.12%)

10:28
06/23/17
06/23
10:28
06/23/17
10:28
Conference/Events
YY management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

SYY

Sysco

$50.78

-1.9958 (-3.78%)

, USFD

US Foods

$26.33

-1.275 (-4.62%)

10:27
06/23/17
06/23
10:27
06/23/17
10:27
Hot Stocks
JPMorgan sees food distributors facing competition from Amazon »

Noting that Amazon's…

SYY

Sysco

$50.78

-1.9958 (-3.78%)

USFD

US Foods

$26.33

-1.275 (-4.62%)

PFGC

Performance Food Group

$26.00

-1.25 (-4.59%)

AMZN

Amazon.com

$1,001.30

-0.93 (-0.09%)

WFM

Whole Foods

$43.20

-0.06 (-0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

ALGN

Align Technology

$149.69

0.27 (0.18%)

10:25
06/23/17
06/23
10:25
06/23/17
10:25
Conference/Events
Stifel medical technology analysts hold an analyst/industry conference call »

Research Team discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.